



SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

Ref: SPL/CORP-SEC/2021-22/BSE/59

Dated: 30.06.2021

To,

Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting with Scrip Code 524703.

A Meeting of the Board of Directors of the Company duly convened on Wednesday, 30th June 2021 **at 05:00 p.m. and Concluded at 5.45 p.m.** discussed the following business:-

1. Considered, Approved and took on record Audited Financial Results for the Quarter and Year ended 31st March 2021.
2. Considered Appointment CS Swapnil J Dixit as Secretarial Auditor of the Company for the Financial Year 2021-22, 2022-23
3. The Board has considered, Analysed and approved receipt of Request from the below mentioned Promoters from **"Promoters Category"** into **"Public Category"**

Sr No	Name of the Promoter /Promoter Group
1	Noumura Realty and Constructions Private Limited
2	Phybrichem Engineers Private Limited
3	Sanmark Realty and Finance Private Limited

You are requested to kindly take the same on record.

Yours Faithfully,



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587





SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

For Sandu Pharmaceuticals Limited



Company Secretary



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN: L24233GA1985PLC001587




SANDU PHARMACEUTICALS LIMITED



Balance Sheet as at 31st, March, 2021

Balance Sheet as at 31st, March, 2021			
PARTICULARS	Note No.	(Rs in lakhs)	
		As at 31st March, 2021	As at 31st March, 2020
		Amount (')	Amount (')
ASSETS			
Non-current assets			
Property, Plant and Equipment	3 (a)	646.57	671.59
Right of use assets	3(b)	963.98	978.57
Other Intangible Assets	4	6.80	10.15
Financial Assets			
Investments	5	24.17	82.36
Loans Receivables	6	-	131.87
Other Financial Asset -Non Current	7	0.43	-
Other Non Current Assets	8	-	24.61
		1,641.95	1,899.15
Current assets			
Inventories	9	1,113.79	1,436.17
Financial Assets			
Trade receivables	10	534.78	468.11
Cash and cash equivalents	11 (a)	452.76	121.66
Bank balances other than (iii) above	11(b)	712.84	32.50
Other current assets	12	240.18	183.59
		3,054.34	2,242.03
		4,696.29	4,141.18
EQUITY AND LIABILITIES			
Equity			
Equity Share capital	13	792.10	708.10
Other Equity	14	2,557.02	2,215.56
		3,349.12	2,923.66
Non-current liabilities			
Financial Liabilities			
Deferred tax liabilities (Net)	15	95.26	84.51
		95.26	84.51
Current liabilities			
Financial Liabilities			
Borrowings	16	1.93	124.50
	17		
Trade payables Due to :			
Dues to Micro & small Enterprises		2.34	3.17
Other Than small & micro enterprises		664.69	572.70
Other current liabilities	18	109.75	114.62
Provisions	19	473.20	318.02
		1,251.91	1,133.01
		4,696.29	4,141.18




SANDU PHARMACEUTICALS LIMITED						
Statement of Profit and Loss for the Period ended 31st March, 2021						
						(Rs in lakhs)
Particulars	Note No.	3 Months ended	Preeceding 3 Months Ended	Corresponding 3 Months ended	Year ended	Year ended
		31 st March 2021	31 St December, 2020	31st March 2020	31st March 2021	31st March 2020
		Audited	Unaudited	Audited	Audited	Audited
INCOME						
Revenue From Operations	20	1,409.54	1576.88	1101.67	5,875.54	4,836.75
Other Income	21	3.07	7.19	4.26	19.34	45.27
Total Income		1,412.61	1,584.07	1,105.93	5,894.88	4,882.02
EXPENSES						
Cost of materials consumed	22	365.45	325.08	280.70	1,187.18	913.85
Purchases of Stock-in-Trade	23	641.34	536.50	552.33	1,924.13	1,700.86
Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	24	-315.85	-44.50	-308.52	338.70	-103.38
Employee benefits expense	25	143.89	319.89	184.72	801.82	685.15
Finance costs	26	5.77	1.39	10.29	11.49	43.48
Depreciation and amortization expense	3	13.81	14.10	13.83	55.67	55.22
Other expenses	27	492.51	389.80	364.58	1,407.80	1,494.71
Total expenses		1,346.91	1,542.26	1,097.93	5,726.79	4,789.89
Profit/(loss) before exceptional items and tax		65.70	41.81	8.00	168.10	92.13
Exceptional Items / Prior Period Adjustment	28	0	0	0	-	0.23
PROFIT/(LOSS) BEFORE TAX		65.70	41.81	8.00	168.10	91.90
Tax expense:	29					
Current tax		17.08	12.28	-9.07	55.71	12.69
Deferred tax		2.30	0.2	0.33	2.95	7.18
Short / (Excess) Tax Provision		0.18			0.18	-
PROFIT (LOSS) FOR THE PERIOD		46.14	29.33	16.74	109.26	72.03
OTHER COMPREHENSIVE INCOME						
Items that will not be reclassified to profit or loss in Subsequent Periods :						
Remeasurement gains/(losses) on post employment defined benefit plans		1.90		-0.76	1.90	(0.76)
Fair value changes of investments		12.01	23.74	-35.51	58.30	(30.34)
Income tax relating to items that will not be reclassified to profit or loss		-2.98	-2.47	3.89	-7.79	3.85
TOTAL OTHER COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX)		10.93	21.27	(32.38)	52.41	(27.25)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX)		57.07	50.60	(15.64)	161.67	44.78
Paid Up Equity Capital (Face Value of Rs 10/- Per share)		708.10	708.10	708.10	708.10	708.10
EARNINGS PER EQUITY SHARE	30					
Basic		0.65	0.41	0.24	1.54	1.02
Diluted		0.65	0.41	0.24	1.54	1.02





Dated : 30/06/2020			For Sandu Pharmaceuticals Ltd	
				
			Umesh Sandu	
			Managing Director	
			DIN :- 01132141	

Statement of changes in equity for the Period ended 31st Mar, 2021

Statement of changes in equity for the Period ended 31st Mar, 2021



SANDU PHARMACEUTICALS LIMITED				
Statement of Cash Flow for the year ended 31st March, 2021				
Particulars	Year ended 31st March, 2021		Year ended 31st March, 2020	
	Amount (₹)	Amount (₹)	Amount (₹)	Amount (₹)
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax		1,68,08,877		91,90,308
Adjustments for:				
Depreciation and amortisation expenses	55,66,953		55,21,731	
Finance costs	11,49,482		43,48,151	
Interest income	(18,88,514)		(1,71,967)	
Dividend income from equity instruments designated at FVTOCI	(45,718)		(45,235)	
Allowance for doubtful debts / expected credit losses - trade receivable	12,52,212		-	
Re-measurement gains/losses on employee defined benefit plans	1,90,570		(75,873)	
		62,24,986		95,76,807
Operating profit / (loss) before changes in operating assets & liabilities		2,30,33,863		1,87,67,115
Changes in operating assets				
(increase) / decrease in inventories	3,22,38,512		(1,10,62,319)	
(increase) / decrease in Trade receivables	(79,18,365)		11,42,962	
(increase) / decrease in other operating assets	60,78,577		3,51,38,252	
Changes in operating liabilities				
(increase) / decrease in trade payables	91,16,445		1,52,51,186	
(increase) / decrease in other operating liabilities	1,79,35,356	5,74,50,524	41,98,287	4,46,68,368
Cash Generated from operation		8,04,84,387		6,34,35,483
Income Tax Paid		(45,83,627)		(14,13,914)
Net Cash flow from Operating activities		7,59,00,760		6,20,21,569
B. Cash flow from investing activities				
Purchases of Property, Plant and Equipment	(12,70,045)		(11,23,242)	
Fixed deposits placed with banks	(6,80,77,330)		(27,63,299)	
Interest received	18,88,514		1,71,967	
Dividend income from equity instruments designated at FVTOCI	45,718		45,235	
Proceeds from sale / redemption of mutual fund designated at FVTOCI	1,16,49,045		-	
Net cash flow from / (used in) investing activities (B)		(5,57,64,098)		(36,69,339)
C. Cash flow from financing activities				
Repayment of long-term borrowings	-		(24,42,803)	
Repayment of Short-term borrowings	(1,22,57,539)		(4,68,04,245)	
Finance cost	(11,49,482)		(43,48,151)	
Proceeds from Issue of Equity Share Capital	1,73,79,538		-	
Share Application Money pending allotment	90,00,120		-	
Net cash flow from / (used in) financing activities (C)		1,29,72,637		(5,35,95,199)
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		3,31,09,299		47,57,030
Cash and cash equivalents at the beginning of the year		1,21,66,415		74,09,386
Cash and cash equivalents at the end of the year		4,52,75,714		1,21,66,415
Place :- Mumbai		For Sandu Pharmaceuticals Ltd		
Date :- 30/06/2021				
		Umesh Sandu		
		Managing Director		
		DIN :- 01132141		




1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 .The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
3. The Figures for the quarter ended 31 st March, 2021 and 31 st March, 2020 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year.
4. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at the meeting held on 30 Th June, 2021.
5. The Company has considered the possible impact of the COVID -19 pandemic on the business operations ,Liquidity Position, and recoverability of it assets balances as a 31 st March 2021 on the internal & external information upto the date of approval of these financials results .The Impact of COVID 19 may be different from that estimated as at the date of approval of these financial results and management wil continue to monitor any material changes arising due to impact of this pandemic on financial and operational performance of the company and take necessary

measures to address the situation.

6. Figures for the previous periods have been reclassified/regrouped, whenever necessary

Date: - 30/06/2021

For Sandu Pharmaceuticals Ltd



A handwritten signature in blue ink, appearing to read "Umesh Sandu", written over a horizontal line.

Umesh Sandu
Managing Director
DIN no: - 01132141



Independent Auditor's Report on Quarterly and Year to date Standalone Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

To,
The Board of Director of,
SANDU PHARMACEUTICALS LIMITED

Report on the Audit of the Standalone Financial Results

Opinion

We have audited the accompanying statements of standalone Financial Results of **SANDU PHARMACEUTICALS LIMITED** ("the Company"), for the quarter and year ended on March 31, 2021 ('the statement') being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended ('the Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, these financial results:

- a. Are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- b. Gives a true and fair view in conformity with the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34") prescribed under Section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the quarter and year ended on March 31, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013(the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the standalone financial results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

We draw your attention to Note 5 to the standalone financial results which states that management has made an assessment of the impact of COVID-19 on the Company's operations, financial performance and position as at and for the year ended March 31, 2021 and has concluded that there is no impact which is required to be recognized in the financial statements. Accordingly, no adjustments have been made to the financial statements. Our opinion is not qualified in respect of this matter.

Management Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate 'internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain Professional skepticism throughout the audit. We also:

- a. Identify and assess the risks of material misstatement of the Standalone financial results, whether due to fraud or error, design and perform audit procedures responsive

to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- b. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company have adequate financial control reference to Financial Statement in place and the operating effectiveness of such control.
- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- d. Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e. Evaluate the overall presentation, structure and content of the Standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

- a. The Statement dealt with by this report has been prepared for the express purpose of filing with BSE Limited. This Statement is based on and should be read with the financial results of the company for the quarter and year ended March 31, 2021 on which we issued an unmodified audit opinion vide our report dated June 30, 2021.

- b. The Statement includes the results for the quarter ended March 31, 2021, being the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures up to December 31, 2020 being the date of the end of the third quarter of the current financial year.

For Dileep & Prithvi
Chartered Accountants

Firm Registration Number: 122290W

HIMMAT Digitally signed by
HIMMAT MAL MALI
MAL MALI Date: 2021.06.30
15:09:45 +05'30'

Himmat Mali

(Partner)

Membership Number: 183378

UDIN: 21183378AAAABZ8591

Place: Mumbai

Date: June 30, 2021



Ref: SPL/CORP-SEC/2020-21/BSE/ 61

Dated: 30.06.2021

To,
Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Scrip Code: 524703

Sub: Declaration regarding Audit Report on Standalone Financial Results for the Quarter and Year ended 31st March 2021 with unmodified opinion of the Independent Auditors.

Dear Sir,

We hereby confirm and declare that the Statutory Auditors of the Company i.e M/s Dileep and Prithvi, Chartered Accountants, Mumbai (Firm No:122290W), have issued the Audit Report on Standalone Financial Results of the Company for the Quarter and Year ended 31st March 2021 with Unmodified opinion.

We submit this declaration as required under the provisions of the Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) 2015 as amended and circular CIR/CFD/CMD/56/2016 May, 2016 issued by SEBI.

You are requested to take the above letter on record.

Yours Faithfully

For Sandu Pharmaceuticals Limited



Umesh B Sandu
Managing Director
DIN: 01132141

AN ISO 9001 : 2015 CERTIFIED ORGANISATION

Corporate Office : P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Opp. D.K. Sandu Chowk, Chembur, Mumbai-400 071
Tel. : +91-22-2528 4402 / 3306. Fax : +91-22-2528 2403. Email : info@sandu.in Web. : www.sandu.in